chr12:25245346:> Detail (hg38) (KRAS)
Information
Genome
| Assembly | Position |
|---|---|
| hg19 | chr12:25,398,280-25,398,285 |
| hg38 | chr12:25,245,346-25,245,351 |
HGVS
| Type | Transcript | Protein |
|---|---|---|
Summary
MGeND
| Clinical significance | |
| Variant entry | |
| GWAS entry | |
| Disease area statistics | Show details |
Frequency
[No Data.]
Prediction
[No Data.]
ClinVar
| Clinical Significance | |
| Review star | [No Data.] |
| Show details | |
Links
Disease area statistics
[No Data.]
MGeND
[No Data.]
ClinVar
[No Data.]
CIViC
| Disease | Drug | EL | ET | ED | CS | VO | TR | Pubmed | Links |
|---|---|---|---|---|---|---|---|---|---|
| colorectal cancer | Chemotherapy,Cetuximab | B |
Predictive
|
Supports
|
Resistance | Somatic | 3 | 20619739 | Detail |
| colorectal cancer | Cetuximab | D |
Predictive
|
Supports
|
Resistance | Somatic | 3 | 18202412 | Detail |
| colorectal cancer | D |
Prognostic
|
Supports
|
Poor Outcome | Somatic | 3 | 18202412 | Detail | |
| lung non-small cell carcinoma | Gefitinib,Erlotinib | B |
Predictive
|
Supports
|
Resistance | Somatic | 3 | 15696205 | Detail |
| pancreatic adenocarcinoma | Gemcitabine,Trametinib | B |
Predictive
|
Supports
|
Resistance | Somatic | 4 | 24915778 | Detail |
| colorectal cancer | B |
Prognostic
|
Does Not Support
|
Poor Outcome | Somatic | 3 | 19603024 | Detail | |
| colorectal cancer | Oxaliplatin | B |
Predictive
|
Does Not Support
|
Resistance | Somatic | 3 | 19603024 | Detail |
| colorectal cancer | Irinotecan | B |
Predictive
|
Does Not Support
|
Resistance | Somatic | 3 | 19603024 | Detail |
| colorectal cancer | Bevacizumab | B |
Predictive
|
Does Not Support
|
Resistance | Somatic | 3 | 19603024 | Detail |
| colorectal cancer | Cetuximab | B |
Predictive
|
Supports
|
Resistance | Somatic | 3 | 19603024 | Detail |
| colorectal cancer | Panitumumab,Cetuximab | B |
Predictive
|
Supports
|
Resistance | Somatic | 3 | 19223544 | Detail |
| pancreatic adenocarcinoma | Trametinib | B |
Predictive
|
Does Not Support
|
Sensitivity/Response | Somatic | 3 | 24915778 | Detail |
DisGeNET
[No Data.]
Annotation
Annotations
| Descrption | Source | Links |
|---|---|---|
| Chemotherapy-refractory patients with metastatic colorectal cancer harboring KRAS mutations (primari... | CIViC Evidence | Detail |
| KRAS mutations were significantly associated with lack of response to cetuximab in patients with adv... | CIViC Evidence | Detail |
| KRAS mutations were significantly associated with reduced progression-free and overall survival in p... | CIViC Evidence | Detail |
| In 60 patients with NSCLC, Exon 2 KRAS mutations were associated with resistance to the EGFR kinase ... | CIViC Evidence | Detail |
| Adding trametinib to gemcitabine does not improve overall survival (OS), progression-free survival (... | CIViC Evidence | Detail |
| This was a retrospective clinical study of 168 metastatic colorectal cancer patients who received fi... | CIViC Evidence | Detail |
| This was a retrospective clinical study of 100 metastatic colorectal cancer patients who received FO... | CIViC Evidence | Detail |
| This was a retrospective clinical study of 44 metastatic colorectal cancer patients who recieved FOL... | CIViC Evidence | Detail |
| This was a retrospective clinical study of 97 metastatic colorectal cancer patients who received bev... | CIViC Evidence | Detail |
| This was a retrospective clinical study of 92 metastatic colorectal cancer patients who received cet... | CIViC Evidence | Detail |
| Mutational analysis of 109 metastatic colorectal cancer patients was used to examine objective tumor... | CIViC Evidence | Detail |
| KRAS G12/G13 status was evaluated in cell-free DNA (cfDNA) of patients with untreated metastatic ade... | CIViC Evidence | Detail |
Overlapped Transcript Coordinates
| Gene | Transcript ID | Exon Number | Chromosome | Start | Stop | Type | Amino Mutation | Transcript Position | Links |
|---|
Overlapped Transcript
| Gene | Transcript ID | Chromosome | Start | Stop | Links |
|---|
- Gene
- -
- Genome
- hg38
- Position
- chr12:25,245,346-25,245,351
- Variant Type
- snv
- Variant (CIViC) (CIViC Variant)
- G12/G13
- Transcript 1 (CIViC Variant)
- ENST00000256078.4
- Variant URL (CIViC Variant)
- https://civic.genome.wustl.edu/links/variants/77
- Summary (CIViC Variant)
- While the KRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort in patients with colorectal and pancreatic cancer, however this hypothesis is in need of further validation. This mutation, along with the mutations affecting the neighboring G13 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. However, cetuximab treatment was shown to extend survival in a cohort of colorectal patients.
Genome browser